Digoxin: The good and the bad

Trends in Cardiovascular Medicine

Volumn 26, Issue 7, 2016, Pages 585-595

  Ziff, Oliver J ^a,b   Kotecha, Dipak ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Atrial fibrillation; Cardiac glycoside; Digoxin; Heart failure; Hospitalization; Mortality; Outcomes.

Indexed keywords

ANTACID AGENT; COLESTYRAMINE; DIGOXIN; ENZYME INDUCING AGENT; GLYCOPROTEIN P INHIBITOR; ANTIARRHYTHMIC AGENT; CARDIOTONIC AGENT;

ATRIAL FIBRILLATION; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART FAILURE; HUMAN; META ANALYSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; HEART CONTRACTION; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HEART VENTRICLE; HOSPITAL ADMISSION; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; DIGOXIN; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART RATE; HEART VENTRICLES; HUMANS; MYOCARDIAL CONTRACTION; PATIENT ADMISSION; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84964771598     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2016.03.011     Document Type: Review

References (68)

1. [1] Withering, W., An account of the foxglove and some of its medical uses with practical remarks on dropsy and other diseases, 1785, G.G.J. and J. Robinson, London.
2. [2] Ziff, O.J., Lane, D.A., Samra, M., et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. Br Med J, 351, 2015, h4451.
3. [3] The Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997), 525–533.
4. [4] Ahmed, A., Rich, M.W., Fleg, J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114 (2006), 397–403.
5. [5] Goldberger, Z.D., Alexander, G.C., Digitalis use in contemporary clinical practice: refitting the foxglove. J Am Med Assoc Intern Med 174 (2014), 151–154.
6. [6] Hussain, Z., Swindle, J., Hauptman, P.J., Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 12 (2006), 343–346.
7. [7] Kotecha, D., Holmes, J., Krum, H., et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384 (2014), 2235–2243.
8. [8] Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004), 43–51.
9. [9] Rathore, S.S., Curtis, J.P., Wang, Y., Bristow, M.R., Krumholz, H.M., Association of serum digoxin concentration and outcomes in patients with heart failure. J Am Med Assoc 289 (2003), 871–878.
10. [10] Smith, T.W., Digitalis. Mechanisms of action and clinical use. N Engl J Med 318 (1988), 358–365.
11. [11] McMahon, W.S., Holzgrefe, H.H., Walker, J.D., et al. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure. J Am Coll Cardiol 28 (1996), 495–505.
12. [12] Sullivan, M., Atwood, J.E., Myers, J., et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol 13 (1989), 1138–1143.
13. [13] Gheorghiade, M. St, Clair, J. St, Clair, C., Beller, G.A., Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 9 (1987), 849–857.
14. [14] Krum, H., Bigger, J.T. Jr, Goldsmith, R.L., Packer, M., Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 25 (1995), 289–294.
15. [15] Newton, G.E., Tong, J.H., Schofield, A.M., Baines, A.D., Floras, J.S., Parker, J.D., Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 28 (1996), 155–161.
16. [16] Dobre, D., Borer, J.S., Fox, K., et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail 16 (2014), 76–85.
17. [17] Schoner, W., Scheiner-Bobis, G., Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs 7 (2007), 173–189.
18. +-ATPase activity in human kidney membrane preparation. Life Sci 88 (2011), 39–42.
19. [19] Pavlovic, D., The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin Pract 128 (2014), 11–21.
20. [20] Iisalo, E., Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2 (1977), 1–16.
21. [21] Rosenbaum, P.R., Rubin, D.B., The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
22. [22] McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
23. [23] Uretsky, B.F., Young, J.B., Shahidi, F.E., Yellen, L.G., Harrison, M.C., Jolly, M.K., Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22 (1993), 955–962.
24. [24] Packer, M., Gheorghiade, M., Young, J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329 (1993), 1–7.
25. [25] Hopper, I., Skiba, M., von Lueder, T.G., et al. Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy—a randomized controlled trial. J Card Fail 21 (2015), 779–781.
26. [26] Adams, K.F. Jr, Gheorghiade, M., Uretsky, B.F., et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 30 (1997), 42–48.
27. [27] Young, J.B., Gheorghiade, M., Uretsky, B.F., Patterson, J.H., Adams, K.F. Jr, Superiority of triple drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective randomized study of ventricular function and efficacy of digoxin. Randomized assessment of digoxin and inhibitors of angiotensin-converting enzyme. J Am Coll Cardiol 32 (1998), 686–692.
28. [28] Ward, R.E., Gheorghiade, M., Young, J.B., Uretsky, B., Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 26 (1995), 93–101.
29. [29] Hopper, I., Samuel, R., Hayward, C., Tonkin, A., Krum, H., Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis. J Card Fail 20 (2014), 522–532.
30. [30] Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
31. [31] Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
32. [32] Nikolaidou, T., Channer, K.S., Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J 85 (2009), 303–312.
33. [33] Kotecha, D., Kirchhof, P., Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med 19 (2014), 222–223.
34. [34] Bavishi, C., Khan, A.R., Ather, S., Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol 188 (2015), 99–101.
35. [35] Chen, Y., Cai, X., Huang, W., Wu, Y., Huang, Y., Hu, Y., Increased all-cause mortality associated with digoxin therapy in patients with atrial fibrillation: an updated meta-analysis. Medicine (Baltimore), 94, 2015, e2409.
36. [36] Hood, W.B. Jr, Dans, A.L., Guyatt, G.H., Jaeschke, R., McMurray, J.J., Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 10 (2004), 155–164.
37. [37] Jaeschke, R., Oxman, A.D., Guyatt, G.H., To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 88 (1990), 279–286.
38. [38] Ouyang, A.J., Lv, Y.N., Zhong, H.L., et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 115 (2015), 901–906.
39. [39] Vamos, M., Erath, J.W., Hohnloser, S.H., Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36 (2015), 1831–1838.
40. [40] Wang, Z.Q., Zhang, R., Chen, M.T., et al. Digoxin is associated with increased all-cause mortality in patients with atrial fibrillation regardless of concomitant heart failure: a meta-analysis. J Cardiovasc Pharmacol 66 (2015), 270–275.
41. [41] Whitbeck, M.G., Charnigo, R.J., Khairy, P., et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 34 (2013), 1481–1488.
42. [42] Gheorghiade, M., Fonarow, G.C., van Veldhuisen, D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34 (2013), 1489–1497.
43. [43] Patel, N.J., Hoosien, M., Deshmukh, A., et al. Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function. Int J Cardiol 169 (2013), e84–e86.
44. [44] Camm, A.J., Kirchhof, P., Lip, G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
45. [45] National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 180, http://www.nice.org.uk/guidance/cg180/, [accessed on 13 April 2014].
46. [46] January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
47. [47] Kotecha, D., Piccini, J.P., Atrial fibrillation in heart failure: what should we do?. Eur Heart J 36 (2015), 3250–3257.
48. [48] Mamas, M.A., Caldwell, J.C., Chacko, S., Garratt, C.J., Fath-Ordoubadi, F., Neyses, L., A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 (2009), 676–683.
49. [49] Kotecha, D., Chudasama, R., Lane, D.A., Kirchhof, P., Lip, G.Y., Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 203 (2016), 660–666.
50. [50] Goldstein, R.E., Boccuzzi, S.J., Cruess, D., Nattel, S., Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83 (1991), 52–60.
51. [51] Fauchier, L., Grimard, C., Pierre, B., et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 103 (2009), 248–254.
52. [52] Chao, T.F., Liu, C.J., Chen, S.J., et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol 30 (2014), 1190–1195.
53. [53] Hallberg, P., Lindback, J., Lindahl, B., Stenestrand, U., Melhus, H., Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 63 (2007), 959–971.
54. [54] Shah, M., Avgil Tsadok, M., Jackevicius, C.A., Essebag, V., Behlouli, H., Pilote, L., Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol 114 (2014), 401–406.
55. [55] Allen, L.A., Fonarow, G.C., Simon, D.N., et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol 65 (2015), 2691–2698.
56. [56] Khand, A.U., Chew, P.G., Douglas, H., Jones, J., Jan, A., Cleland, J.G., The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation. Cardiology 130 (2015), 153–158.
57. [57] Sonnenblick, M., Abraham, A.S., Meshulam, Z., Eylath, U., Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed) 286 (1983), 1089–1091.
58. [58] Dasgupta, A., Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol 118 (2002), 132–140.
59. [59] Adams, K.F. Jr, Patterson, J.H., Gattis, W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46 (2005), 497–504.
60. [60] Adams, K.F. Jr, Gheorghiade, M., Uretsky, B.F., Patterson, J.H., Schwartz, T.A., Young, J.B., Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39 (2002), 946–953.
61. [61] Teerlink, J.R., Sliwa, K., Opie, L.H., Heart failure. Opie, L.H., Gersh, B.J., (eds.) Drugs for the heart, 8th ed., 2013, Elsevier Saunders, Philadelphia, 169–223.
62. [62] Matzke, G.R., Frye, R.F., Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 16 (1997), 205–231.
63. [63] Bauman, J.L., DiDomenico, R.J., Viana, M., Fitch, M., A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 166 (2006), 2539–2545.
64. [64] Smith, T.W., Antman, E.M., Friedman, P.L., Blatt, C.M., Marsh, J.D., Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 26 (1984), 413–458.
65. [65] Elliott, P.M., Anastasakis, A., Borger, M.A., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 (2014), 2733–2779.
66. [66] Kelly, R.A., Smith, T.W., Recognition and management of digitalis toxicity. Am J Cardiol 69 (1992), 108G–118G [disc. 118G-119G].
67. [67] Hannover Medical School, German Federal Ministry of Education and Research. Digitoxin to improve outcomes in patients with advanced systolic chronic heart failure. European Union Clinical Trials Register 2014. EudraCT Number: 2013-005326-38, Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-005326-38/DE [accessed on 10 August 2015].
68. [68] Institute of Cardiovascular Sciences; University of Birmingham. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF). National Library of Medicine (US) 2015. NLM Identifier: NCT02391337, Available from: https://clinicaltrials.gov/ct2/show/NCT02391337 [accessed on 20 November 2015].